Given the results of KEYNOTE-A18, do you plan to recommend adding pembrolizumab to primary chemoradiotherapy for advanced stage cervical cancer?

If so, will you recommend it universally or only for certain patient population(s)?

Answer from: Radiation Oncologist at Academic Institution

Until the paper gets published, we won't really know a lot of details that may influence the potential utility of this regimen. It has an abstract/presentation and has recently received FDA approval.It is a relatively 'newer' idea in improving outcomes that we as an institution are open to start off...

Comments

Radiation Oncologist at Harbin Clinic
Any updates on this question given the March and s...

Radiation Oncologist at Vanderbilt-Ingram Cancer Center
So the publication (Lorusso et al., PMID 38521086)...

Please select the option that best describes you:

Given the results of KEYNOTE-A18, do you plan to recommend adding pembrolizumab to primary chemoradiotherapy for advanced stage cervical cancer?

Related Questions